Inve India ▾

Aurobindo Pharma share price & results

Aurobindo Pharma Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Hyderabad pharma maker of generic formulations & APIs sold in 150+ countries; scaling biosimilars via CuraTeQ.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue9,150 ₹ crore+16.3% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin21.0 %+1.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit1,032 ₹ crore+25.2% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity10.72 %−0.9 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin7.33 %+2.9 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)9.09 %−3.3 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

4 of 7 judged targets kept · 13 open · verdicts reflect calls analysed to Q1 FY27.

Aurobindo Pharma Limited management guidance track record on Inve: 20 targets tracked across analysed earnings calls (4 achieved, 3 missed, 13 open).

TargetOriginal wordingSaidLatest callVerdict
M&A Closure Timeline9 months as a matter of abundant caution (by Q4 FY26)
Call transcript, Q1 FY26 · 5 Aug 2025		Q1 FY26Q1 FY27:Successfully completed the acquisition during Q1 FY27, ahead of the revised 'early Q2' timeline.
Call transcript, Q1 FY27 · 6 Aug 2026		Achieved
EBITDA Margin21% to 22% for FY25
Call transcript, Q3 FY25 · 7 Feb 2025		Q3 FY25Q1 FY27:Promise relates to FY25 and is concluded. Not discussed.
Call transcript, Q1 FY27 · 6 Aug 2026		Missed
Business Inflection Year2028 to 2030 will be the inflection point
Call transcript, Q3 FY25 · 7 Feb 2025		Q3 FY25Q1 FY27:Progress continues with imminent US filings and 4 approvals in EU/UK/Canada. Management reiterated target of 7-8 products by 2028-29.
Call transcript, Q1 FY27 · 6 Aug 2026		On Track

Source: Inve Guidance Tracker for Aurobindo Pharma Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

3 of Aurobindo Pharma Limited's 20 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 17 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹1,627.5 +2.36% · +₹37.5

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +50.0% 1Y

₹1.2k₹1.4k₹1.6kOct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 6 Nov 2025Q3 FY26 — 10 Feb 2026Q4 FY26 — 22 May 2026Q1 FY27 — 6 Aug 2026

1Y: ₹1,085 on 24 Oct 2025 → ₹1,627.5. High ₹1,734 (18 Sept 2026), low ₹1,085 (24 Oct 2025).

Previous close
₹1,590
Market cap
₹93.6k Cr
52-week range
₹1,094.7 – ₹1,734
One year
+48.67%
Price to earnings (TTM to Jun 2026)
24.77×
Return on equity (TTM to Jun 2026)
10.72%

Overview

Symbol
NSE:AUROPHARMA
Exchange
NSE
Currency
INR

What Aurobindo Pharma Limited does

Based on the company's own presentations, annual report and earnings calls.

Aurobindo Pharma is a Hyderabad-headquartered pharmaceutical company that develops, manufactures and markets generic finished-dosage formulations (oral solids, injectables and specialty products) and active pharmaceutical ingredients (APIs) across therapeutic areas such as CNS, cardiovascular, antibiotics, antiretrovirals, anti-diabetics, gastroenterology, oncology and dermatology. It earns primarily by exporting formulations to the US and Europe, with additional sales to growth markets and ARV tenders, while its API business supplies both its own formulation plants and external customers. The group is also building newer businesses in complex injectables/specialty products (Eugia Pharma), biosimilars (CuraTeQ Biologics) and contract manufacturing of biologics for global pharma partners (TheraNym).

Segments

  • Formulations
  • Active Pharmaceutical Ingredients (API)
  • Biosimilars & Biologics CDMO
Manufacturing and packaging facilities
31 globally
Countries of presence
150+
R&D centres worldwide
9
Global workforce
40,000+
Formulation (FDF) facilities
18
API & intermediates facilities
13
Headquarters Hyderabad, Telangana, India Company website

How the price took the results

close before → close after

Q1 FY27
−1.5%
6 Aug
Q4 FY26
−5.4%
22 May
Q3 FY26
−6.6%
10 Feb
Q2 FY26
−0.7%
6 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Aurobindo Pharma Limited

Free account: one company. Everything above stays public.

Write why you follow Aurobindo Pharma Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Aurobindo Pharma Limited

Guides on how to read this kind of business and the numbers that matter.